Induction of IGHV3-53 public antibodies with broadly neutralising activity against SARS-CoV-2 including Omicron subvariants in a Delta breakthrough infection caseResearch in context

Autor: Takeo Kuwata, Yu Kaku, Shashwata Biswas, Kaho Matsumoto, Mikiko Shimizu, Yoko Kawanami, Ryuta Uraki, Kyo Okazaki, Rumi Minami, Yoji Nagasaki, Mami Nagashima, Isao Yoshida, Kenji Sadamasu, Kazuhisa Yoshimura, Mutsumi Ito, Maki Kiso, Seiya Yamayoshi, Masaki Imai, Terumasa Ikeda, Kei Sato, Mako Toyoda, Takamasa Ueno, Takako Inoue, Yasuhito Tanaka, Kanako Tarakado Kimura, Takao Hashiguchi, Yukihiko Sugita, Takeshi Noda, Hiroshi Morioka, Yoshihiro Kawaoka, Shuzo Matsushita, Jumpei Ito, Naoko Misawa, Arnon Plianchaisuk, Ziyi Guo, Alfredo Hina, Jr., Keiya Uriu, Kaoru Usui, Wilaiporn Saikruang, Spyridon Lytras, Ryo Yoshimura, Shusuke Kawakubo, Luca Nishimura, Yusuke Kosugi, Shigeru Fujita, Luo Chen, Jarel Elgin M. Tolentino, Lin Pan, Wenye Li, Maximilian Stanley Yo, Kio Horinaka, Mai Suganami, Adam P. Strange, Mika Chiba, Keiko Iida, Naomi Ohsumi, Kaho Okumura, Shiho Tanaka, Eiko Ogawa, Kyoko Yasuda, Tsuki Fukuda, Rina Osujo, Takasuke Fukuhara, Tomokazu Tamura, Rigel Suzuki, Saori Suzuki, Hayato Ito, Keita Matsuno, Hirofumi Sawa, Naganori Nao, Shinya Tanaka, Masumi Tsuda, Lei Wang, Yoshikata Oda, Zannatul Ferdous, Kenji Shishido, Keita Mizuma, Isshu Kojima, Jingshu Li, Tomoya Tsubo, Shuhei Tsujino, So Nakagawa, Kotaro Shirakawa, Akifumi Takaori-Kondo, Kayoko Nagata, Ryosuke Nomura, Yoshihito Horisawa, Yusuke Tashiro, Yugo Kawai, Kazuo Takayama, Rina Hashimoto, Sayaka Deguchi, Yukio Watanabe, Ayaka Sakamoto, Naoko Yasuhara, Tateki Suzuki, Kanako Kimura, Jiei Sasaki, Yukari Nakajima, Hisano Yajima, Yoshitaka Nakata, Hiroki Futatsusako, Takashi Irie, Ryoko Kawabata, Kaori Tabata, Hesham Nasser, Ryo Shimizu, MST Monira Begum, Michael Jonathan, Yuka Mugita, Otowa Takahashi, Kimiko Ichihara, Chihiro Motozono, Sharee Leong, Akatsuki Saito, Maya Shofa, Yuki Shibatani, Tomoko Nishiuchi, Hiroyuki Asakura, Jiri Zahradnik, Prokopios Andrikopoulos, Miguel Padilla-Blanco, Aditi Konar

Publikováno v: EBioMedicine, Vol 110, Iss , Pp 105439- (2024)

Summary: Background: Emergence of SARS-CoV-2 variants that escape neutralising antibodies hampers the development of vaccines and therapeutic antibodies against SARS-CoV-2. IGHV3-53/3-66-derived public antibodies, which are generally specific to the

Externí odkaz: https://doaj.org/article/e91f95c836a440f4825df3e5b712b6d7

Inadequate structural constraint on Fab approach rather than paratope elicitation limits HIV-1 MPER vaccine utility

Autor: Kemin Tan, Junjian Chen, Yu Kaku, Yi Wang, Luke Donius, Rafiq Ahmad Khan, Xiaolong Li, Hannah Richter, Michael S. Seaman, Thomas Walz, Wonmuk Hwang, Ellis L. Reinherz, Mikyung Kim

Publikováno v: Nature Communications, Vol 14, Iss 1, Pp 1-14 (2023)

Abstract Broadly neutralizing antibodies (bnAbs) against HIV-1 target conserved envelope (Env) epitopes to block viral replication. Here, using structural analyses, we provide evidence to explain why a vaccine targeting the membrane-proximal external

Externí odkaz: https://doaj.org/article/47bc63ae82264e1ca90081493607b6de

Development and characterization of a panel of anti-idiotype antibodies to 1C10 that cross-neutralize HIV-1 subtype B viruses

Autor: Yu Kaku, Kaho Matsumoto, Takeo Kuwata, Hasan Md Zahid, Shashwata Biswas, Miroslaw K. Gorny, Shuzo Matsushita

Publikováno v: Frontiers in Virology, Vol 2 (2022)

The V3 loop of the human immunodeficiency virus type 1 (HIV-1) envelope protein (Env) is one of the conserved immunogenic regions targeted by neutralizing antibodies (nAb). Two different binding modes of anti-V3 abs have been reported in studies usin

Externí odkaz: https://doaj.org/article/f6e462b2b5cf4ef491c08cf908dfbdc8

Functional analysis of a monoclonal antibody reactive against the C1C2 of Env obtained from a patient infected with HIV-1 CRF02_AG

Autor: Shokichi Takahama, Kaho Matsumoto, Shuzo Matsushita, Hasan Md Zahid, Yu Kaku, Hirokazu Tamamura, Shashwata Biswas, Takeo Kuwata

Publikováno v: Retrovirology, Vol 18, Iss 1, Pp 1-15 (2021)
Retrovirology

Background Recent data suggest the importance of non-neutralizing antibodies (nnAbs) in the development of vaccines against HIV-1 because two types of nnAbs that recognize the coreceptor binding site (CoRBS) and the C1C2 region mediate antibody-depen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af8d0d259c532c3c0177d3f204d9080
https://doaj.org/article/7af56d9df31d47318c4a1a4855b83946

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19

Autor: Kaho Matsumoto, Yukiko Muramoto, Yoshio Koyanagi, Hiroshi Takahashi, Chihiro Motozono, Takeo Kuwata, Terumasa Ikeda, Kazuya Shimura, Takamasa Ueno, Yoji Nagasaki, Yosuke Maeda, Shuzo Matsushita, Takao Hashiguchi, Tsuneyuki Tatsuke, Takeshi Noda, Hajime Iwagoe, Shashwata Biswas, Kazuhiko Fujii, Tateki Suzuki, Mako Toyoda, Mikiko Shimizu, Hiroto Kishi, Noriko Kuramoto, Jiei Sasaki, Hasan Md Zahid, Chiho Onishi, Rumi Minami, Yu Kaku, Yoko Kawanami

Publikováno v: Cell Reports
Cell Reports, Vol 36, Iss 2, Pp 109385-(2021)

Administration of plasma from convalescent patients or neutralizing monoclonal antibodies (mAbs) is potent therapeutic option for COVID-19 caused by SARS-CoV-2 infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9f93ab503c5ffaf24e74d4dae1a4064d
http://europepmc.org/articles/PMC8226103